Want to see AGL full AI Analyst Report?
AGL Stock Chart & Stats
$96.11
-$2.27(-2.26%)
At close: 4:00 PM EDT
$96.11
-$2.27(-2.26%)
Day’s Range― - ―
52-Week Range$7.48 - $133.04
Previous CloseN/A
Volume247.62K
Average Volume (3M)218.12K
Market Cap
$1.54B
Enterprise Value$1.62B
Total Cash (Recent Filing)$185.63M
Total Debt (Recent Filing)$33.45M
Price to Earnings (P/E)―
Beta2.70
Next Earnings
Nov 04, 2026EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend Yield0.23%
Share Statistics
EPS (TTM)-15.38
Shares Outstanding16,791,210
10 Day Avg. Volume185,073
30 Day Avg. Volume218,116
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.25
Price to Sales (P/S)0.05
P/FCF Ratio-2.40
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue0.27
Enterprise Value/Gross Profit19.77K
Enterprise Value/Ebitda-6.93
Forecast
1Y Price Target
$117.56Price Target Upside22.31% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)-2.33
Revenue Forecast (FY)$5.83B
Bulls Say, Bears Say
Bulls Say
Operating TurnaroundThe sharp improvement in adjusted EBITDA and higher full-year guidance indicate that operating performance can improve materially as medical economics stabilize. Sustained profitability would strengthen internal funding capacity, support investment in care programs, and reduce dependence on external capital over the next several quarters.
Clinical Program ExecutionDemonstrated savings and strong quality outcomes support Agilon’s value proposition to physicians and payers in risk-based Medicare care. Effective clinical pathways can improve medical-cost performance, reinforce partner retention, and create a durable advantage as reimbursement increasingly rewards quality and total-cost control.
Data And Liquidity FoundationBroader payer data coverage should improve identification of high-risk patients and visibility into revenue and medical costs, supporting better decisions in risk contracts. Combined with substantial reported liquidity, this gives Agilon resources to execute clinical investments and manage volatility while scaling its platform.
Bears Say
Persistent Losses And Cash BurnContinued losses and negative operating and free cash flow show that the business has not yet become self-funding despite recent operational improvement. Ongoing cash consumption can constrain investment flexibility, increase reliance on the balance sheet, and make durable earnings conversion dependent on further medical-margin gains.
Medicare Advantage Membership DeclineA smaller Medicare Advantage member base reduces the population over which Agilon can earn capitation and generate shared-savings economics. Although management prioritized profitability, sustained membership contraction could limit scale benefits, weaken growth in attributed revenue, and increase the importance of retention and contract execution.
Medical Cost Trend PressureElevated medical-cost trends directly pressure margins in contracts where Agilon shares responsibility for total care costs. Conservative reserving and limited claims visibility add uncertainty to reported performance, while persistent cost inflation could offset clinical savings and make the recent profitability improvement harder to sustain.
Agilon Health News
AGL FAQ
What was Agilon Health’s price range in the past 12 months?
Agilon Health lowest stock price was $7.48 and its highest was $133.04 in the past 12 months.
What is Agilon Health’s market cap?
Agilon Health’s market cap is $1.54B.
When is Agilon Health’s upcoming earnings report date?
Agilon Health’s upcoming earnings report date is Nov 04, 2026 which is in 12 days.
How were Agilon Health’s earnings last quarter?
Agilon Health released its earnings results on Aug 05, 2026. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.144 by $0.896.
Is Agilon Health overvalued?
According to Wall Street analysts Agilon Health’s price is currently Undervalued.
Does Agilon Health pay dividends?
Agilon Health pays a Quarterly dividend of $0.45 which represents an annual dividend yield of 0.23%. See more information on Agilon Health dividends here
What is Agilon Health’s EPS estimate?
Agilon Health’s EPS estimate is -1.23.
How many shares outstanding does Agilon Health have?
Agilon Health has 16,791,210 shares outstanding.
What happened to Agilon Health’s price movement after its last earnings report?
Agilon Health reported an EPS of $1.04 in its last earnings report, beating expectations of $0.144. Following the earnings report the stock price went down -19.49%.
Which hedge fund is a major shareholder of Agilon Health?
Currently, no hedge funds are holding shares in AGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agilon Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$117.56 (22.31% Upside)
$117.56 (22.31% Upside)
Blogger Sentiment
Bullish
AGL Sentiment 83%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 7.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
286.99%
12-Months-Change
Fundamentals
Return on Equity
-119.35%
Trailing 12-Months
Asset Growth
-7.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agilon Health
Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As of December 31, 2021, the company served an approximate total of 238,000 senior clients. This figure included 186,300 individuals enrolled in Medicare Advantage plans and 51,700 recipients of Medicare fee-for-service benefits. The enterprise, which commenced operations in 2016, was initially incorporated as Agilon Health Topco, Inc. before rebranding to its current name, agilon health, inc., in March 2021. Its corporate headquarters are situated in Austin, Texas.
AGL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized materially improved financial performance in Q2 (revenue growth, a large swing to positive medical margin, and a return to positive adjusted EBITDA), uplift from better-than-expected risk adjustment and stronger clinical program execution (CHF, Burden of Illness, ACO REACH). Management also highlighted enhanced data capabilities and ongoing AI/clinical pathway investments as durability drivers. Offsets and near-term risks include a year-over-year decline in MA membership driven by disciplined contracting, ongoing cost trend pressures (conservative reserving and ~7% cost trend assumptions for the back half), Part D exposure complexities, and uncertainty around 2027 contracting and membership. Overall, positives (financial turnaround, risk adjustment uplift, clinical program outcomes, and improved data visibility) outweigh the operational and timing headwinds, supporting constructive visibility into 2026 and a cautiously optimistic view into 2027.View all AGL earnings summariesAGL Stock 12 Month Forecast
Average Price Target
$117.56
▲(22.31% Upside)
Technical Analysis
National Healthcare
―
Astrana Health
―
Clinigence Holdings
―
InnovAge Holding
―
P3 Health Partners
―
Ownership Overview
5.63% Insiders
16.51% Mutual Funds
0.13% Other Institutional Investors
67.08% Public Companies and
Individual Investors